Thursday, May 20, 2021
9:12 AM EST – BioVaxys Technology Corp. : Announced the appointment of Adam Coutts, PhD, as Policy Advisor. Dr. Coutts is a Senior Research Fellow at Magdalene College, University of Cambridge and a Research Associate in the Department of Sociology, University of Cambridge. Dr. Coutts’ research focuses on the social and political determinants of health looking at how non-health sector public policies affect the health and wellbeing of vulnerable groups and how government interventions can be used to help them. Dr. Coutts holds a PhD from the Department of Sociology, University of Cambridge and has held post-doctoral fellowships at Cambridge , and the Department of Politics and International Relations, University of Oxford, Nuffield College. Dr. Coutts is also a research associate at the Centre for Business Research, Cambridge. James Passin , BioVaxys CEO, stated, “We are honored to onboard Dr. Coutts as a Policy Advisor to BioVaxys. Dr. Coutts’ expertise and experience in public health policy, bringing together academic, policy decision makers and multilateral agencies with those working on-the-ground to deliver healthcare, will prove critical as BioVaxys advances CoviDTH, a novel skin test for T cell immunity to Covid-19, through regulatory and commercial development. We believe that CoviDTH can offer a transformative approach to public health policy in low-income contexts especially in humanitarian and conflict settings, where resources and access are limited. This approach provides a tool to help governments optimize the distribution and targeting of vaccines which will accelerate the lifting of restrictions and lockdown policies.” BioVaxys Technology Corp. (C.BIOV) shares were unchanged at 0.24.
Stocks in Play: BioVaxys Technology Corp., Thu, 20 May 2021 09:27:06 EST